Stephane Zuily

Nancy, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Dosage of lipoproteins for risk management according to guidelines.

Dosage of lipoproteins for risk management according to guidelines.

Journal: Vascular diseases (Paris, France)

Published: March 18, 2026

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Journal: Journal of the American College of Cardiology

Published: March 16, 2026

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Journal: Thrombosis and haemostasis

Published: January 28, 2026

A high level of sTREM-1 predicts occurrence of thrombosis, obstetrical event or death in a prospective cohort of patients with antiphospholipid antibodies and/or systemic lupus. Results of the APLART study.

A high level of sTREM-1 predicts occurrence of thrombosis, obstetrical event or death in a prospective cohort of patients with antiphospholipid antibodies and/or systemic lupus. Results of the APLART study.

Journal: Lupus

Published: November 14, 2025

"Should anticoagulation therapy be discontinued in a patient whose antiphospholipid antibodies have become negative?": The con

"Should anticoagulation therapy be discontinued in a patient whose antiphospholipid antibodies have become negative?": The con

Journal: La Revue de medecine interne

Published: June 30, 2025

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Journal: Current rheumatology reports

Published: March 05, 2025

Response to: Correspondence on '2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria' by Yeng et al.

Response to: Correspondence on '2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria' by Yeng et al.

Journal: Annals of the rheumatic diseases

Published: March 02, 2025

Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome.

Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome.

Journal: Circulation

Published: February 05, 2025

Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.

Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.

Journal: Annals of internal medicine

Published: December 23, 2024

A presentation of posterior reversible encephalopathy syndrome after heart transplantation: a case report and review of literature.

A presentation of posterior reversible encephalopathy syndrome after heart transplantation: a case report and review of literature.

Journal: Journal of medical case reports

Published: December 04, 2024

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.

Journal: Lancet (London, England)

Published: November 22, 2024

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Journal: Arthritis care & research

Published: September 11, 2024

Showing 1-12 of 144

Last Updated: 09/26/2026